Aprea Therapeutics (APRE) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aprea Therapeutics is the larger company by market cap ($7.0 million vs $152,759), about 46.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | MDCX |
|---|---|---|
| Share price | $0.5582 | $0.1019 |
| Market cap | $7.03M | $152.76K |
| 1-day change | -7.74% | -36.39% |
| YTD return | — | -93.34% |
| 1-year return | — | -95.86% |
| EPS (TTM) | $-0.95 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $139.00 |
| 52-week low | $0.548 | $0.0941 |
| Distance from 52-week high | -66.97% | -99.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +568.22% | +4316.09% |
| Average volume | 280.14K | 92.96K |
| Shares outstanding | 12.59M | 1.50M |
| Employees | 8 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Aprea Therapeutics is about 46.0 times larger than Medicus Pharma by market value ($7.03M vs $152.76K).
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
APRE vs MDCX FAQ
Which is bigger, Aprea Therapeutics or Medicus Pharma?
Aprea Therapeutics (APRE) is larger, with a market capitalization of $7.03M compared with $152.76K for Medicus Pharma (MDCX).
Are Aprea Therapeutics and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.